Cue Announces Positive Topline Results From CUE-221 Phase 2 Study
Cue Biopharma reported successful Phase 2 results in chronic spontaneous urticaria, meeting primary endpoints with statistical significance and demonstrating a favorable safety profile. The positive data support advancement to Phase 2b/3 registration trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed